Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5713 and REGN5715 in Allergic Conjunctivitis Due to Birch Pollen Allergy
NCT07309432Phase 3Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bremzalerbart, atisnolerbart in allergic conjunctivitis (AC), sponsored by Regeneron Pharmaceuticals. Started Jan 2026; status: terminated.
02
Drugs
bremzalerbartatisnolerbart
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT07309432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07309432.